Clobetasol or Pimecrolimus for Vulvar Lichen Sclerosus?

For genital lichen sclerosus, potent or ultrapotent topical corticosteroids remain standard treatment. The 2026 S3 guideline for German-speaking countries suggests calcineurin inhibitors, including pimecrolimus, as a second choice or addition when corticosteroids are insufficient or contraindicated.¹

What did the creams trial test?

The 2011 double-blind trial enrolled 38 women with active vulvar lichen sclerosus; 36 were analyzed. Over 12 weeks, participants used pimecrolimus 1% cream twice daily or clobetasol 0.05% cream in the evening, with inactive cream in the morning.²

The primary outcome was inflammation on paired skin biopsies. Clobetasol improved this more than pimecrolimus. No improvement in biopsy inflammation occurred in 1/19 clobetasol users versus 8/17 pimecrolimus users. Itching and burning/pain improved in both groups, without a statistically significant between-group difference. That does not establish equal symptom effects.²

Novartis funded the trial. Its short duration and small sample cannot settle long-term safety or cancer-prevention outcomes.²

How does that fit current treatment?

The S3 guideline recommends ointments rather than creams or gels for lichen sclerosus, so the exact preparations in this older trial matter. It also recommends emollients alongside standard therapy.¹

If a steroid seems ineffective, bring the tube and your actual application schedule. Ask the clinician to check the diagnosis, application area and amount, and possible irritation or infection before choosing a substitute. The guideline recommends investigating other causes when the skin or symptoms worsen.¹

Our lichen sclerosus follow-up checks cover maintenance instructions and skin changes to report.

What needs explaining about pimecrolimus?

Its US label covers second-line treatment of mild-to-moderate eczema, making lichen sclerosus use off-label. The label warns that long-term safety has not been established and advises avoiding continuous long-term use. Rare cancers have been reported with topical calcineurin inhibitors, without an established causal link.³

It is for external skin, not inside the vagina. Burning or stinging can occur. Ask for written instructions specific to the diagnosed vulvar condition, including when to report irritation and how the treatment will be reviewed. An eczema cream’s package directions cannot replace that plan.³

Down There, Decoded discusses lichen sclerosus in “The Itch That Isn’t Yeast.” Its Down-There Log records symptom location, skin changes, products used and dates. Bring those notes to the treatment review. See the book.